WHY NEGATIVE RESULTS IN CLINICAL TRIALS MATTER
International Clinical Trials Day 2026, a year in review: Trial of The Year 2025
With
Professor Brett J. Manley, Consultant Neonatologist
Mercy Hospital For Women, Melbourne &
Professor of Neonatal Medicine,
Department of Obstetrics, Gynaecology and Newborn Health,
University of Melbourne, Australia
Kate Francis, Biostatistician (Snr Research Officer)
Murdoch Children’s Research Institute, Melbourne &
Honorary Research Fellow,
Department of Paediatrics,
University of Melbourne &
Affiliate Biostatistician, The Royal Children’s Hospital, Melbourne, Australia
Professor Christopher Reid, Chair
Australian Clinical Trials Alliance (ACTA) &
School of Public Health and Preventive Medicine, Monash University &
School of Population Health at Curtin University,
Western Australia
A BENCH SIDE STORY SYNDICATION
Filmed in Melbourne & Perth | May 2026
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
The aim of the PLUSS trial was to find out if installation of budesonide (a steroid) with surfactant to the lungs of extremely preterm babies helps to prevent lung disease, or Bronchopulmonary dysplasia (BPD).
BPD is a chronic inflammatory lung disease characterised by disordered alveolar and vascular development, most commonly affecting extremely preterm infants exposed to mechanical ventilation and oxygen therapy for respiratory distress syndrome (RDS). BPD is associated with mortality, and adverse long-term pulmonary and neurodevelopmental outcomes. Despite advances in neonatal care including antenatal corticosteroids, exogenous surfactant, and the increasing use of non-invasive respiratory support, the incidence of BPD has increased in the state of Victoria in 2005 compared with earlier eras.
Extremely preterm infants participating in the trial were monitored closely after birth and an assessment completed at 36 weeks to check for BPD. Participating infants were also followed up when they are two years old.
The trial was led by a team of researchers at the Royal Women’s Hospital, Melbourne and the Liggins Institute in Auckland, New Zealand and had 29 participating centres around the world.
In 2025 the PLUSS Trial received the Australian Clinical Trials Alliance (ACTA) Trial of the Year 2025 Award as well as the ACTA STInG Excellence in Trial Statistics Award2025.
Source: Adapted from plusstrial.org website
As seen on Bench Side Story
-
Allied Health Building Leadership Experience in Tasmania
A notable program run by Hospitals South is the ABLE program, or Allied Health Building Leadership Experience. This program was created to address the challenge of allied health professionals being seen as a single entity, rather than as individual disciplines, when it comes to leadership and management opportunities. The program is delivered entirely internally, with seminars presented by senior staff and mentorship opportunities for participants to become more effective representatives of allied health in meetings and working groups.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
-
Harnessing the skillset and availability of the nation’s Exercise Physiologists and Scientists
Katie Lyndon MBA, BAppSci, ESSAF, FACHSM, CHE, AEP, AES, GAICD, CHIA, is an allied health professional and executive leader with nearly two decades of experience spanning executive leadership, delivery of strategic programs across the health system and clinical care.
As CEO of Exercise & Sports Science Australia (ESSA), Katie brings a unique blend of frontline experience and strategic vision to advance the profession and advocate for evidence-based exercise in preventive health and chronic disease management. Her long-standing commitment to ESSA includes serving as Board Vice President, Policy and Advocacy Manager, Standards Council member and ESSA Fellow.
